T
r
e
a
t
i
n
g
T
r
e
a
t
m
e
n
t
Resistant Depression
Ketabon – accessing ketamine’s
antidepressant potential
We develop a potential take-at-home treatment option for the 94 million patients suffering from Treatment-Resistant Depression (TRD) globally.
KET01 is an oral prolonged-release formulation of ketamine. It therefore combines the robust and rapid efficacy of ketamine with superior tolerability, patient convenience, and accessibility compared to current treatment options.
A growing burden
on patients and society
More and more people are suffering from neuropsychiatric disorders, globally. Depression stands out as the most prevalent mental health disease. Especially burdensome for patients and society is Treatment-Resistant Depression (TRD), having immense societal and economic costs which currently are not addressed adequately.
Mental Disorders
Treating Treatment-
Resistant Depression
Ketabon aims to unlock ketamine’s full antidepressant potential while at the same time substantially limiting its side effects. We are developing an oral prolonged release formulation of ketamine (KET01) that has the potential to overcome the drawbacks of other ketamine formulations.
Arguably the greatest breakthrough
in the field of depression in
over 60 years
Ketamine is known to have significant antidepressant potential. Its rapid antidepressant effects in TRD-patients especially through intravenous infusions are well studied. Patients describe improvement of depressive symptoms within a matter of hours, which last up to one week. While efficacious, currently applied ketamine treatments including intranasal esketamine come with several limitations.
Change the future of treating
Treatment-Resistant Depression with us
We are always open for new partners and fellow pioneers to share our vision of how we treat Treatment Resistant Depression. Join us today or receive more information via the contact below.
Katharina Schwabe
About
Ketabon
Ketabon is a joint venture between HMNC Brain Health and Develco Pharma. The company develops an oral prolonged-release formulation of ketamine for Treatment-Resistant Depression (TRD) with minimal dissociative side effects. This prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects due to its unique pharmacokinetic profile compared to the currently applied intravenous and intranasal ketamine therapies. TRD patients with insufficient response to standard antidepressants represent 30% of an overall estimated number of 320 million patients worldwide suffering from major depressive disorder. In this group, prolonged-release ketamine has shown high response rates. Clinical development of oral prolonged-release ketamine could also potentially be expanded into other indications.
Dr. Markus Zimmer
Co-CEO
Dr. Maximilian Döbler
Co-CEO
Dr. Hans Eriksson
CMO
Potential first-line
treatment option
The clinical data to date strongly suggest KET01 as a potential first-line treatment option for Treatment-Resistant Depression. The early read-out from a Proof-of-Concept investigator-initiated clinical trial in 27 TRD patients just recently reaffirmed KET01’s efficacy and tolerability potential.
mean MADRS score,
Day 15
Current Phase 2 trial
and preparing near-term market entry
Based on the promising results from the Proof-of-Concept trial, we initiated a multicenter, double-blind, randomized, placebo-controlled Phase 2 trial in Germany, the Czech Republic and Poland. The study investigates the efficacy, safety, and tolerability of add-on treatment with ketamine hydrochloride prolonged-release tablets (KET01) in patients suffering from Treatment-Resistant Depression.
